7,536 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Mirador Capital Partners LP

Mirador Capital Partners LP acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 7,536 shares of the company's stock, valued at approximately $297,000.

Several other large investors also recently bought and sold shares of the business. Capital Market Strategies LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter valued at $461,000. Capital Advisors Inc. OK lifted its holdings in CRISPR Therapeutics by 8.1% in the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company's stock valued at $14,122,000 after acquiring an additional 22,583 shares during the period. Geode Capital Management LLC boosted its position in CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company's stock worth $47,383,000 after purchasing an additional 35,196 shares during the last quarter. Granite Bay Wealth Management LLC bought a new stake in shares of CRISPR Therapeutics during the 2nd quarter valued at about $2,375,000. Finally, State Street Corp increased its position in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after purchasing an additional 599,304 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CRSP has been the topic of a number of research reports. JMP Securities reissued a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a report on Friday, December 20th. Royal Bank of Canada reissued a "sector perform" rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Needham & Company LLC restated a "buy" rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday. Barclays lowered their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Wednesday, November 6th. Finally, Chardan Capital restated a "buy" rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $78.38.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the completion of the transaction, the chief executive officer now owns 181,540 shares of the company's stock, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Stock Performance

Shares of CRSP traded up $0.23 during midday trading on Friday, hitting $40.53. 1,367,113 shares of the company traded hands, compared to its average volume of 1,765,932. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $91.10. The firm has a 50 day moving average of $45.23 and a 200-day moving average of $48.25. The stock has a market cap of $3.46 billion, a price-to-earnings ratio of -14.32 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the prior year, the company earned ($1.41) earnings per share. Sell-side analysts predict that CRISPR Therapeutics AG will post -5.13 earnings per share for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.